Back to homepage

Dermatology

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Authors: Martina Burlando, Riccardo Castelli, Emanuele Cozzani, Aurora Parodi

Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs in Context 2021; 10: 2021-2-6. DOI: 10.7573/dic.2021-2-6

More▸

Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic

Authors: Tiago Torres, Marta Pereira, Maria João Paiva Lopes, Clarisse Rebelo, Pedro Andrade, Martinha Henrique, Hugo Oliveira, Paulo Ferreira, Gabriela Marques Pinto, Francisco Menezes Brandão, Jorge Rozeira, Paulo Filipe, Rui Tavares Bello

This article describes the real-life strategies and therapeutic options adopted by dermatologists regarding their patients with psoriasis being treated with or with an indication for systemic therapy during the first COVID-19 lockdown period in Portugal.

More▸

Bimekizumab: the new drug in the biologics armamentarium for psoriasis

Authors: Egídio Freitas, Tiago Torres

Bimekizumab is mentioned in the recent report by Clarivate, Drugs to Watch in 2021, as one of the drugs to be observed in 2021. This article discusses the current status of bimekizumab.

More▸

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis

Authors: Giovanna Malara, Gabriella Fabbrocini, Caterina Trifirò, Martina Burlando

The aim of the article is to describe a clinical experience aimed at increasing tolerability of dimethyl fumarate.

More▸

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Authors: Martina Burlando, Riccardo Castelli, Emanuele Cozzani, Aurora Parodi

This article reports experiences with tildrakizumab as they may be helpful to dermatologists to maximize the
efficiency of this therapy.

More▸